719 related articles for article (PubMed ID: 17030231)
1. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
Bleecker ER; Yancey SW; Baitinger LA; Edwards LD; Klotsman M; Anderson WH; Dorinsky PM
J Allergy Clin Immunol; 2006 Oct; 118(4):809-16. PubMed ID: 17030231
[TBL] [Abstract][Full Text] [Related]
2. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.
Bleecker ER; Nelson HS; Kraft M; Corren J; Meyers DA; Yancey SW; Anderson WH; Emmett AH; Ortega HG
Am J Respir Crit Care Med; 2010 Apr; 181(7):676-87. PubMed ID: 19910613
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
4. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
Bateman ED; Kornmann O; Schmidt P; Pivovarova A; Engel M; Fabbri LM
J Allergy Clin Immunol; 2011 Aug; 128(2):315-22. PubMed ID: 21807250
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
8. The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.
Konno S; Hizawa N; Makita H; Shimizu K; Sakamoto T; Kokubu F; Saito T; Endo T; Ninomiya H; Iijima H; Kaneko N; Ito YM; Nishimura M;
Pharmacogenet Genomics; 2014 May; 24(5):246-55. PubMed ID: 24681963
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Pearlman DS; White MV; Lieberman AK; Pepsin PJ; Kalberg C; Emmett A; Bowers B; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):227-35. PubMed ID: 11868930
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Nelson HS; Busse WW; Kerwin E; Church N; Emmett A; Rickard K; Knobil K
J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891
[TBL] [Abstract][Full Text] [Related]
12. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Wechsler ME; Kunselman SJ; Chinchilli VM; Bleecker E; Boushey HA; Calhoun WJ; Ameredes BT; Castro M; Craig TJ; Denlinger L; Fahy JV; Jarjour N; Kazani S; Kim S; Kraft M; Lazarus SC; Lemanske RF; Markezich A; Martin RJ; Permaul P; Peters SP; Ramsdell J; Sorkness CA; Sutherland ER; Szefler SJ; Walter MJ; Wasserman SI; Israel E;
Lancet; 2009 Nov; 374(9703):1754-64. PubMed ID: 19932356
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
15. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
Malone R; LaForce C; Nimmagadda S; Schoaf L; House K; Ellsworth A; Dorinsky P
Ann Allergy Asthma Immunol; 2005 Jul; 95(1):66-71. PubMed ID: 16095144
[TBL] [Abstract][Full Text] [Related]
16. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.
Israel E; Chinchilli VM; Ford JG; Boushey HA; Cherniack R; Craig TJ; Deykin A; Fagan JK; Fahy JV; Fish J; Kraft M; Kunselman SJ; Lazarus SC; Lemanske RF; Liggett SB; Martin RJ; Mitra N; Peters SP; Silverman E; Sorkness CA; Szefler SJ; Wechsler ME; Weiss ST; Drazen JM;
Lancet; 2004 Oct 23-29; 364(9444):1505-12. PubMed ID: 15500895
[TBL] [Abstract][Full Text] [Related]
17. [A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination].
Grosclaude M; Cerruti JL; Delannay B; Hérent M; Spilthooren F; Desfougères JL
Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):356-62. PubMed ID: 14716965
[TBL] [Abstract][Full Text] [Related]
18. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.
Bleecker ER; Postma DS; Lawrance RM; Meyers DA; Ambrose HJ; Goldman M
Lancet; 2007 Dec; 370(9605):2118-25. PubMed ID: 18156033
[TBL] [Abstract][Full Text] [Related]
19. [Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
Miyagawa T
Arerugi; 2008 Nov; 57(11):1134-44. PubMed ID: 19052508
[TBL] [Abstract][Full Text] [Related]
20. Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.
Kobayashi Y; Yasuba H; Kudou M; Kita H
J Asthma; 2007 Mar; 44(2):77-81. PubMed ID: 17454319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
